[1] |
YU YC, MAO YM, CHEN CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury[J]. Hepatol Int, 2017, 11( 3): 221- 241. DOI: 10.1007/s12072-017-9793-2.
|
[2] |
BJÖRNSSON ES, BERGMANN OM, BJÖRNSSON HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144( 7): 1419- 1425. DOI: 10.1053/j.gastro.2013.02.006.
|
[3] |
SGRO C, CLINARD F, OUAZIR K, et al. Incidence of drug-induced hepatic injuries: A French population-based study[J]. Hepatology, 2002, 36( 2): 451- 455. DOI: 10.1053/jhep.2002.34857.
|
[4] |
SHEN T, LIU YX, SHANG J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156( 8): 2230- 2241. e 11. DOI: 10.1053/j.gastro.2019.02.002.
|
[5] |
CHALASANI N, BONKOVSKY HL, FONTANA R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study[J]. Gastroenterology, 2015, 148( 7): 1340- 1352. e 7. DOI: 10.1053/j.gastro.2015.03.006.
|
[6] |
LICATA A, MINISSALE MG, CALVARUSO V, et al. A focus on epidemiology of drug-induced liver injury: Analysis of a prospective cohort[J]. Eur Rev Med Pharmacol Sci, 2017, 21( 1 Suppl): 112- 121.
|
[7] |
CHALASANI N, FONTANA RJ, BONKOVSKY HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States[J]. Gastroenterology, 2008, 135( 6): 1924- 1934. e1- e4. DOI: 10.1053/j.gastro.2008.09.011.
|
[8] |
BJORNSSON ES, JONASSON JG. Drug-induced cholestasis[J]. Clin Liver Dis, 2013, 17( 2): 191- 209. DOI: 10.1016/j.cld.2012.11.002.
|
[9] |
LAMMERT C, IMLER T, TEAL E, et al. Patients with chronic liver disease suggestive of nonalcoholic fatty liver disease may be at higher risk for drug-induced liver injury[J]. Clin Gastroenterol Hepatol, 2019, 17( 13): 2814- 2815. DOI: 10.1016/j.cgh.2018.12.013.
|
[10] |
BESSONE F, DIRCHWOLF M, RODIL MA, et al. Review article: Drug-induced liver injury in the context of nonalcoholic fatty liver disease-a physiopathological and clinical integrated view[J]. Aliment Pharmacol Ther, 2018, 48( 9): 892- 913. DOI: 10.1111/apt.14952.
|
[11] |
CHALASANI N, ALJADHEY H, KESTERSON J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity[J]. Gastroenterology, 2004, 126( 5): 1287- 1292. DOI: 10.1053/j.gastro.2004.02.015.
|
[12] |
RUSSO MW, HOOFNAGLE JH, GU JZ, et al. Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network[J]. Hepatology, 2014, 60( 2): 679- 686. DOI: 10.1002/hep.27157.
|
[13] |
WATKINS PB, SELIGMAN PJ, PEARS JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury[J]. Hepatology, 2008, 48( 5): 1680- 1689. DOI: 10.1002/hep.22633.
|
[14] |
FONTANA RJ, HAYASHI PH, BARNHART H, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury[J]. Am J Gastroenterol, 2015, 110( 10): 1450- 1459. DOI: 10.1038/ajg.2015.283.
|
[15] |
BJÖRNSSON E, DAVIDSDOTTIR L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice[J]. J Hepatol, 2009, 50( 3): 511- 517. DOI: 10.1016/j.jhep.2008.10.021.
|
[16] |
YOKODA RT, RODRIGUEZ EA. Review: Pathogenesis of cholestatic liver diseases[J]. World J Hepatol, 2020, 12( 8): 423- 435. DOI: 10.4254/wjh.v12.i8.423.
|
[17] |
Chinese Society of Hepatology, Chinese Medical Association. Guideline on the management of cholestasis liver diseases[J]. J Clin Hepatol, 2022, 38( 1): 62- 69.
中华医学会肝病学分会. 胆汁淤积性肝病管理指南(2021年)[J]. 临床肝胆病杂志, 2022, 38( 1): 62- 69.
|
[18] |
GOSSARD AA, TALWALKAR JA. Cholestatic liver disease[J]. Med Clin North Am, 2014, 98( 1): 73- 85. DOI: 10.1016/j.mcna.2013.09.002.
|
[19] |
SARCOGNATO S, SACCHI D, GRILLO F, et al. Autoimmune biliary diseases: Primary biliary cholangitis and primary sclerosing cholangitis[J]. Pathologica, 2021, 113( 3): 170- 184. DOI: 10.32074/1591-951X-245.
|
[20] |
PINZANI M, LUONG TV. Pathogenesis of biliary fibrosis[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864( 4 Pt B): 1279- 1283. DOI: 10.1016/j.bbadis.2017.07.026.
|
[21] |
JANSEN PLM, GHALLAB A, VARTAK N, et al. The ascending pathophysiology of cholestatic liver disease[J]. Hepatology, 2017, 65( 2): 722- 738. DOI: 10.1002/hep.28965.
|
[22] |
CHALASANI NP, MADDUR H, RUSSO MW, et al. ACG clinical guideline: Diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2021, 116( 5): 878- 898. DOI: 10.14309/ajg.0000000000001259.
|
[23] |
BJÖRNSSON HK, BJÖRNSSON ES. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management[J]. Eur J Intern Med, 2022, 97: 26- 31. DOI: 10.1016/j.ejim.2021.10.035.
|
[24] |
NORMAN BH. Drug induced liver injury(DILI). Mechanisms and medicinal chemistry avoidance/mitigation strategies[J]. J Med Chem, 2020, 63( 20): 11397- 11419. DOI: 10.1021/acs.jmedchem.0c00524.
|
[25] |
LARREY D, ERLINGER S. Drug-induced cholestasis[J]. Baillieres Clin Gastroenterol, 1988, 2( 2): 423- 452. DOI: 10.1016/0950-3528(88)90010-3.
|
[26] |
BESSONE F, HILLOTTE GL, AHUMADA N, et al. UDCA for drug-induced liver disease: Clinical and pathophysiological basis[J]. Semin Liver Dis, 2024, 44( 1): 1- 22. DOI: 10.1055/s-0044-1779520.
|
[27] |
HU PF, WANG PQ, CHEN H, et al. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury[J]. J Dig Dis, 2016, 17( 9): 618- 627. DOI: 10.1111/1751-2980.12383.
|
[28] |
HIRSCHFIELD GM, DYSON JK, ALEXANDER GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J]. Gut, 2018, 67( 9): 1568- 1594. DOI: 10.1136/gutjnl-2017-315259.
|
[29] |
FLOREANI A, de MARTIN S. Treatment of primary sclerosing cholangitis[J]. Dig Liver Dis, 2021, 53( 12): 1531- 1538. DOI: 10.1016/j.dld.2021.04.028.
|
[30] |
ASCHENBRENNER DS. Excessive dosing of obeticholic acid may increase risk of liver damage[J]. Am J Nurs, 2018, 118( 2): 46. DOI: 10.1097/01.NAJ.0000530245.53335.c8.
|
[31] |
U.S. Food and Drug Administration(FDA). FDA drug safety communication: FDA warns about serious liver injury with ocaliva(obeticholic acid) for rare chronic liver disease[EB/OL].[ 2024-05-30]. https://www.fda.gov/media/104801/download. https://www.fda.gov/media/104801/download
|
[32] |
U.S. National Institutes of Health(NIH). LiverTox: Clinical and research information on drug-induced liver injury[EB/OL].[ 2024-05-30]. https://livertox.nlm.nih.gov. https://livertox.nlm.nih.gov
|
[33] |
HIRSCHFIELD GM, MASON A, LUKETIC V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J]. Gastroenterology, 2015, 148( 4): 751- 761. e 8. DOI: 10.1053/j.gastro.2014.12.005.
|
[34] |
KOWDLEY KV, LUKETIC V, CHAPMAN R, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J]. Hepatology, 2018, 67( 5): 1890- 1902. DOI: 10.1002/hep.29569.
|
[35] |
NEVENS F, ANDREONE P, MAZZELLA G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375( 7): 631- 643. DOI: 10.1056/NEJMoa1509840.
|
[36] |
QUIGLEY G, AL ANI M, NADIR A. Occurrence of jaundice following simultaneous ursodeoxycholic acid cessation and obeticholic acid initiation[J]. Dig Dis Sci, 2018, 63( 2): 529- 532. DOI: 10.1007/s10620-017-4900-8.
|
[37] |
HASEGAWA S, YONEDA M, KURITA Y, et al. Cholestatic liver disease: Current treatment strategies and new therapeutic agents[J]. Drugs, 2021, 81( 10): 1181- 1192. DOI: 10.1007/s40265-021-01545-7.
|
[38] |
ZHANG JP. Pathological diagnosis of cholestatic liver disease[J]. J Clin Hepatol, 2024, 40( 6): 1093- 1099. DOI: 10.12449/JCH240605.
张继平. 胆汁淤积性肝病的病理学诊断[J]. 临床肝胆病杂志, 2024, 40( 6): 1093- 1099. DOI: 10.12449/JCH240605.
|
[39] |
BAI HH, FENG HJ, GUO LJ, et al. An analysis on the clinical biochemical and pathological characteristics of simple cholestatic type of drug induced liver injury[J]. Chin Hepatol, 2024, 29( 1): 37- 40, 55. DOI: 10.14000/j.cnki.issn.1008-1704.2024.01.011.
白欢欢, 冯惠君, 郭立杰, 等. 单纯淤胆型药物性肝损伤临床生化及病理特点分析[J]. 肝脏, 2024, 29( 1): 37- 40, 55. DOI: 10.14000/j.cnki.issn.1008-1704.2024.01.011.
|
[40] |
ALLISON R, GURAKA A, SHAWA IT, et al. Drug induced liver injury-a 2023 update[J]. J Toxicol Environ Health B Crit Rev, 2023, 26( 8): 442- 467. DOI: 10.1080/10937404.2023.2261848.
|
[41] |
WEILER S, MERZ M, KULLAK-UBLICK GA. Drug-induced liver injury: The dawn of biomarkers?[J]. F1000Prime Rep, 2015, 7: 34. DOI: 10.12703/P7-34.
|
[42] |
KWO PY, COHEN SM, LIM JK. ACG clinical guideline: Evaluation of abnormal liver chemistries[J]. Am J Gastroenterol, 2017, 112( 1): 18- 35. DOI: 10.1038/ajg.2016.517.
|
[43] |
BJÖRNSSON E, TALWALKAR J, TREEPRASERTSUK S, et al. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis[J]. Hepatology, 2010, 51( 6): 2040- 2048. DOI: 10.1002/hep.23588.
|
[44] |
DELEMOS AS, FOUREAU DM, JACOBS C, et al. Drug-induced liver injury with autoimmune features[J]. Semin Liver Dis, 2014, 34( 2): 194- 204. DOI: 10.1055/s-0034-1375959.
|
[45] |
SUZUKI A, BRUNT EM, KLEINER DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury[J]. Hepatology, 2011, 54( 3): 931- 939. DOI: 10.1002/hep.24481.
|
[46] |
BÉNICHOU C. Criteria of drug-induced liver disorders. Report of an international consensus meeting[J]. J Hepatol, 1990, 11( 2): 272- 276. DOI: 10.1016/0168-8278(90)90124-a.
|
[47] |
YOUNOSSI ZM, BERNSTEIN D, SHIFFMAN ML, et al. Diagnosis and management of primary biliary cholangitis[J]. Am J Gastroenterol, 2019, 114( 1): 48- 63. DOI: 10.1038/s41395-018-0390-3.
|
[48] |
FEJFAR T, VAŇÁSEK T, HŮLEK P. Chronic cholestatic liver diseases-Primary biliary cholangitis and Primary sclerosing cholangitis[J]. Vnitr Lek, 2020, 66( 5): 287- 300.
|
[49] |
BLUM HE. Chronic cholestatic liver diseases[J]. J Gastroenterol Hepatol, 2002, 17( Suppl 3): S399- S402. DOI: 10.1046/j.1440-1746.17.s3.34.x.
|
[50] |
PADDA MS, SANCHEZ M, AKHTAR AJ, et al. Drug-induced cholestasis[J]. Hepatology, 2011, 53( 4): 1377- 1387. DOI: 10.1002/hep.24229.
|
[51] |
TRIVEDI PJ, HIRSCHFIELD GM. Recent advances in clinical practice: Epidemiology of autoimmune liver diseases[J]. Gut, 2021, 70( 10): 1989- 2003. DOI: 10.1136/gutjnl-2020-322362.
|
[52] |
LI XY, TANG JT, MAO YM. Incidence and risk factors of drug-induced liver injury[J]. Liver Int, 2022, 42( 9): 1999- 2014. DOI: 10.1111/liv.15262.
|